Group 1 - The company, Prolog Pharma, announced that its wholly-owned subsidiary, Zhejiang Jutai Pharmaceutical Co., Ltd., received a drug registration certificate for Cefaclor capsules from the National Medical Products Administration [1] - The drug is indicated for bacterial infections caused by Streptococcus and other bacteria sensitive to Cefaclor [1] - The projected market size for the Chinese hospital market in 2024 is 455 million capsules, with a sales value of 387 million yuan [1] Group 2 - As of the announcement date, the total R&D investment for Cefaclor capsules amounted to 6.1 million yuan [1] - Obtaining the registration certificate is equivalent to passing the consistency evaluation of generic drug quality and efficacy, which qualifies the product for subsequent centralized procurement [1] - This development is expected to enhance the company's market competitiveness [1]